1.Bone functions as a novel endocrine organ in energy metabolism.
Xiang CHEN ; Hao-ming TIAN ; Fu-xing PEI ; Xi-jie YU
Chinese Medical Journal 2012;125(22):4117-4121
2.Integrative Physiology: Defined Novel Metabolic Roles of Osteocalcin.
Yu Sik KIM ; Il Young PAIK ; Young Jun RHIE ; Sang Hoon SUH
Journal of Korean Medical Science 2010;25(7):985-991
The prevailing model of osteology is that bones constantly undergo a remodeling process, and that the differentiation and functions of osteoblasts are partially regulated by leptin through different central hypothalamic pathways. The finding that bone remodeling is regulated by leptin suggested possible endocrinal effects of bones on energy metabolism. Recently, a reciprocal relationship between bones and energy metabolism was determined whereby leptin influences osteoblast functions and, in turn, the osteoblast-derived protein osteocalcin influences energy metabolism. The metabolic effects of bones are caused by the release of osteocalcin into the circulation in an uncarboxylated form due to incomplete gamma-carboxylation. In this regard, the Esp gene encoding osteotesticular protein tyrosine phosphatase is particularly interesting because it may regulate gamma-carboxylation of osteocalcin. Novel metabolic roles of osteocalcin have been identified, including increased insulin secretion and sensitivity, increased energy expenditure, fat mass reduction, and mitochondrial proliferation and functional enhancement. To date, only a positive correlation between osteocalcin and energy metabolism in humans has been detected, leaving causal effects unresolved. Further research topics include: identification of the osteocalcin receptor; the nature of osteocalcin regulation in other pathways regulating metabolism; crosstalk between nutrition, osteocalcin, and energy metabolism; and potential applications in the treatment of metabolic diseases.
Bone Remodeling/physiology
;
Bone and Bones/*metabolism
;
*Energy Metabolism
;
Humans
;
Leptin/metabolism
;
Osteocalcin/genetics/*metabolism
3.Expression of osteopontin and osteocalcin during distraction osteogenesis on rhesus with cleft palate.
Yan-Shan LIU ; Gang CHEN ; Yi LIU ; Rui LI ; Zhi-Qi WANG ; Dai SHEN
Chinese Journal of Plastic Surgery 2009;25(5):365-368
OBJECTIVETo study the mechanism of new bone formation and remodeling of distraction osteogenesis (DO) by analysis of the expression of osteopontin (OPN) and osteocalcin (OC).
METHODSRhesus were operated to reconstruct the animal model of cleft palate (CP). The CP was closed by DO in experimental group(n = 21). After consolidation of 1, 2, 4, 6, 8, 12, 24 weeks, every 3 animals were killed to collect the specimens, respectively. The OPN and OC and their mRNA were detected quantitatively by Real-time RT-PCR and ELISA, respectively. The animals in control group (n = 2) and sham group (n = 2) were used as control.
RESULTSThe mRNA expression of OPN increased since 2nd week of consolidation and reached the peak at 4th week (7.59 +/- 0.37). The mRNA expression of OC was up-regulated since 4th week, and reach the peak at 6th week (7.94 +/- 0.31). Then they decreased to about the level in sham group at 24th week (P > 0.05). The OPN and OC were highly expressed during 4 to 6 weeks of consolidation. During 8 to 12 weeks, they decreased like their mRNA expression.
CONCLUSIONThe intramembraneous new bone formation after DO can reconstruct the bone defect of CP. The new formed bone can be remodeled to be quite normal bone tissue.
Animals ; Cleft Palate ; metabolism ; surgery ; Macaca mulatta ; Osteocalcin ; metabolism ; Osteogenesis, Distraction ; Osteopontin ; metabolism
4.An "endocrine function of" bone to pick: starting with males.
Protein & Cell 2011;2(3):171-172
Animals
;
Bone and Bones
;
metabolism
;
physiology
;
Endocrine System
;
metabolism
;
physiology
;
Female
;
Humans
;
Male
;
Osteocalcin
;
metabolism
5.Biological effects of nano-hydroxyapatite/polyamide 66 on the osteoblast.
Ling YE ; Qin SU ; Xue-dong ZHOU
West China Journal of Stomatology 2005;23(2):142-144
OBJECTIVETo evaluate the biological effects of nano-hydroxyapatite/polyamide 66(nHA-PA66) on the growth and activity of osteoblast.
METHODSMTT assay was used to determine the growth of osteoblast, enzymatic measure was used to determine the activity of ALP and quantitative RT-PCR (QRT-PCR) to evaluate the changes of osteoclacin mRNA expression in osteoblasts treated by DMEM eluate of nHA-PA66.
RESULTSOsteoblasts of different test groups demonstrated relative proliferation rate ranging from 98% - 106% without dose-dependent effect. The ALP activity and osteocalcin mRNA expression were similar in test and control groups (P > 0.05).
CONCLUSIONnHA-PA66 has no negative effects on the osteoblast and its osteoblast-compatibility is proved.
Durapatite ; pharmacology ; Nylons ; pharmacology ; Osteoblasts ; drug effects ; Osteocalcin ; metabolism ; RNA, Messenger ; metabolism
6.Bone and Energy Metabolism.
Journal of Korean Diabetes 2013;14(4):174-177
Bone remodeling requires a large amount of energy, and is regulated by various hormones. Leptin, produced by adipocytes, is a well-known regulator of energy balance and is also involved in controlling bone mass through interaction with the central nervous system. Serotonin, downstream of leptin, is also emerging as a candidate for controlling energy balance and bone metabolism. Currently, bone is also considered to be an endocrine regulator of energy metabolism. Osteocalcin, secreted from osteoblasts, is known to be a key regulator of glucose and fat metabolism. In this review, we describe a novel concept that asserts that there exists a biological link between bone and energy metabolism, and we summarize what is currently known about the relationship between bone and energy metabolism.
Adipocytes
;
Bone Remodeling
;
Central Nervous System
;
Energy Metabolism*
;
Glucose
;
Leptin
;
Metabolism
;
Neurotransmitter Agents
;
Osteoblasts
;
Osteocalcin
;
Serotonin
7.Effects of 275 nm and 310 nm ultraviolet irradiation on bone metabolism in ovariectomized osteoporotic rats.
Wei HE ; Si Wen YANG ; Juan CHEN ; Xiao Jun ZHU ; Zhi Zhong CHEN ; Wen Jun MA
Journal of Peking University(Health Sciences) 2022;54(2):236-243
OBJECTIVE:
To investigate the effect of 275 nm and 310 nm ultraviolet irradiation on ovariectomized rats' bone metabolism.
METHODS:
Twenty four 3-month-old female Sprague-Dawley (SD) rat were randomly divided into control group, sham operated group, 275 nm ultraviolet (UV) irradiation group and 310 nm UV irradiation group. Each group contained 6 rats. The rats in the two irradiation groups were treated with bilateral ovariectomy. The rats in sham operated group received sham operation (They were given the same back incision and a bit of par-ovarian fat were removed). Control group received no disposition. About 24 weeks after operation, all the rats received detailed bone mineral density (BMD) detection again. Detection regions include cervical vertebra, lumbar vertebra, proximal femur, mid femur and distal femur. Next, osteopenia rats in 275 nm irradiation group were UV irradiated 275 nm with fixed illumination intensity (15 μW/cm2) everyday for 16 weeks. The osteopenia rats in 310 nm irradiation group were UV irradiated 310 nm with fixed illumination intensity (15 μW/cm2) everyday for 16 weeks. The backs of the rats were shaved regularly as irradiation area (6 cm×8 cm). After 16-week irradiation, all the rats' BMD of cervical vertebra, lumbar vertebra, proximal femur, mid femur and distal femur were measured. At the end of the trial, all the rats' blood specimens were obtained and serum 25(OH)D, procollagen type Ⅰ N-peptide (PINP) and osteocalcin (OC) were measured.
RESULTS:
Compared with control group [(238.78±26.74) mg/cm3], the BMD of the whole body were significantly lower in 275 nm [(193.34±13.28) mg/cm3] and 310 nm [(191.19±18.48) mg/cm3] irradiation groups (P=0.002, P=0.001). There were no significant difference between sham operated group [(227.20±14.32) mg/cm3] and control group. After 16-week ultraviolet irradiation, the BMD of the whole body were significantly increased in 275 nm [(193.34±13.28) mg/cm3 vs. (221.68±25.52) mg/cm3, P=0.005] and 310 nm groups [(191.19±18.48) mg/cm3 vs. (267.48±20.54) mg/cm3, P < 0.001] after corresponding irradiation. The BMD of the four body regions (lumbar vertebra, proximal femur, mid femur and distal femur) had significantly increased after irradiation in 275 nm irradiation group. For 310 nm irradiation group, the BMD in cervical vertebra, lumbar vertebra, proximal femur, mid femur and distal femur also had increased significantly after 310 nm ultraviolet irradiation. The concentration of serum 25(OH)D and OC was higher in 275 nm irradiation group than in control group [(46.78±5.59) μg/L vs. (21.32±6.65) μg/L, P=0.002;(2.05±0.53) U/L vs. (1.32±0.07) U/L, P=0.022]. Compared with the control, the concentration of serum 25(OH)D [(58.05±12.74) μg/L], OC [(2.04±0.53) U/L] and PINP [(176.16±24.18) U/L] was significantly higher (P < 0.001, P=0.015, P=0.005) in 310 nm irradiation group. However, there were no significantly difference between sham operated group and the control.
CONCLUSION
Both 275 nm and 310 nm ultraviolet could improve rats' vitamin D synthesis. Both 275 nm and 310 nm ultraviolet could improve osteopenia rats' bone condition. The irradiation of 310 nm might be more effective on bone condition improvement.
Animals
;
Bone Density
;
Bone Diseases, Metabolic/metabolism*
;
Female
;
Femur/metabolism*
;
Humans
;
Osteocalcin/metabolism*
;
Ovariectomy
;
Rats
;
Rats, Sprague-Dawley
8.The Effects of Estrogen Replacement Therapy and Pamidronate on the Bone Metabolism of Postmenopausal Women.
Korean Journal of Obstetrics and Gynecology 2002;45(2):285-291
OBJECTIVE: To evaluate the effects of estrogen replacement therapy and pamidronate on the bone metabolism in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of oral pamidronate and conjugated equine estrogen, in combination and seperately, on biochemical markers of bone turnover in 140 women with low bone mass. Treatment included pamidronate (group I, n=50), or conjugated equine estrogen (group II, n=50), conjugated equine estrogen plus alendronate (group III, n=40) for 12 months. Biochemical markers of bone turnover were also measured at months 6 and 12 months. RESULTS: Serum osteocalcin and urinary deoxypyridinoline in Group I, Group II and Group III decreased signifiantly at 12 months of treatment (p<0.05). But total alkaline phosphatase decreased significantly during the treatment in Group III, but not in Group I and Group II. CONCLUSION: The combined treatment with pamidronate and conjugated equine estrogen is more effective in postmenopausal women with osteoporosis by decreasing bone biochemical markers.
Alendronate
;
Alkaline Phosphatase
;
Biomarkers
;
Estrogen Replacement Therapy*
;
Estrogens*
;
Female
;
Humans
;
Metabolism*
;
Osteocalcin
;
Osteoporosis
;
Postmenopause
;
Prospective Studies
9.Effect of Ultraviolet Irradiation on Bone Metabolism: Serologic & Radiological Study in Mouse.
In Ho JEON ; Jae Hwan JEONG ; Hyun Kee LEE ; Jung Sook JIN ; Youn Kwan JUNG ; Hyo Jin KIM ; Hee Jung JIN ; So Hyun PARK ; Rae Joon PARK ; Im Hee SHIN ; Je Yong CHOI
Journal of Korean Orthopaedic Research Society 2006;9(2):165-175
PURPOSE: The purpose of this study was to investigate the effects of low energy-ultraviolet B (UVB) irradiation on bone metabolism and turnover in mice. MATERIALS AND METHODS: Five-week old C57BL/6 mice were randomly allocated into two groups. Control group (n=35) was not exposed to UVB and experimental group (n=35) was exposed to low energy-UVB for 30 min a day during 7 days. Serological and radiological examination was performed at 0, 1, 2, 4, 8 week(s) of each group (n=7). RESULTS: Analysis of biochemical bone markers revealed that alkaline phosphatase (ALP) was detected higher in the UVB group compared to control group. Serum level of osteocalcin was higher in UVB group at 1st week after UVB irradiation (p=0.031). The mean value of Vitamin D was significantly higher in UVB group than control group (p=0.032). Bone mineral density (BMD) from both 5th lumbar spine (p=0.124) and femur (p=0.862) showed higher in UVB group than control group from two weeks after irradiation, but they were not statistically significant. CONCLUSION: Our study with radiological bone mineral density and serological tests for biochemical bone turnover markers revealed that ultraviolet irradiation contributed positive effect on bone formation.
Alkaline Phosphatase
;
Animals
;
Bone Density
;
Femur
;
Metabolism*
;
Mice*
;
Osteocalcin
;
Osteogenesis
;
Serologic Tests
;
Spine
;
Vitamin D
10.A Comparison of the effect of Synthetic Hormone Replacement therapy on Bone Mineral Density and Biochemical markers of Bone metabolism.
Joo Long LEE ; Seong Yun JEONG ; Jae Gun SUNWOO ; Dong Han BAE
Korean Journal of Obstetrics and Gynecology 2002;45(3):465-469
OBJECTIVE: To determine the effect of hormone replacement therapy on bone mineral density and biochemical marker of bone metabolism in postmenopausal women receiving hormone replacement therapy. METHOD: We have treated two groups of menopausal women for 4 years; Group 1 received Conjugated Equine Estrogen 0.625 mg (Premarin(R)); Group 2 received Cyclic combined therapy, estrogen and progestin, (Premarin(R) 0.625 mg per day, Provera(R) 10mg per day for 12days), Group 1 was hysterectomized women, received Conjugated Equine Estrogen 0.625 mg per day. We compared the change of bone marker, osteocalcin and bone mineral density during therapy. RESULT: The data demonstrated a beneficial effect in bone marker, osteocalcin decreased in two groups from the baseline values. And hormone replacement therapy shows the beneficial effect in bone mineral densities. Spine BMD increased in two groups by 3.67%, 3.04% after 4years. Femur BMD increased in two groups by 5.34%, 5.25% from the initial value after 4 years. CONCLUSION: Our study results suggest that single estrogen therapy and cyclic combined therapy have benificial effect on increased BMD and decreased bone marker, osteocalcin. Their effects were not signigicantly different between two groups.
Biomarkers*
;
Bone Density*
;
Estrogens
;
Female
;
Femur
;
Hormone Replacement Therapy*
;
Humans
;
Metabolism*
;
Osteocalcin
;
Spine